Bioinformatics Analysis and Validation of Potential Markers Associated with Prediction and Prognosis of Gastric Cancer
Open accessThe DOI matches its Crossref record; 117 of the 119 references it cites were found in a registry or an index; 88 of the 108 sources its claims cite were checked for support.
Abstract
Gastric cancer (GC) is one of the most common cancers worldwide. Most patients are diagnosed at the progressive stage of the disease, and current anticancer drug advancements are still lacking. Therefore, it is crucial to find relevant biomarkers with the accurate prediction of prognoses and good predictive accuracy to select appropriate patients with GC. Recent advances in molecular profiling technologies, including genomics, epigenomics, transcriptomics, proteomics, and metabolomics, have enabled the approach of GC biology at multiple levels of omics interaction networks. Systemic biological analyses, such as computational inference of "big data" and advanced bioinformatic approaches, are emerging to identify the key molecular biomarkers of GC, which would benefit targeted therapies. This review summarizes the current status of how bioinformatics analysis contributes to biomarker discovery for prognosis and prediction of therapeutic efficacy in GC based on a search of the medical literature. We highlight emerging individual multi-omics datasets, such as genomics, epigenomics, transcriptomics, proteomics, and metabolomics, for validating putative markers. Finally, we discuss the current challenges and future perspectives to integrate multi-omics analysis for improving biomarker implementation. The practical integration of bioinformatics analysis and multi-omics datasets under complementary computational analysis is having a great impact on the search for predictive and prognostic biomarkers and may lead to an important revolution in treatment.
Overview
CoChat Summary
TL;DR
This narrative review summarizes how bioinformatics and single- or multi-omics analyses have been used to identify predictive and prognostic biomarkers in gastric cancer across genomics, epigenomics, transcriptomics, proteomics, metabolomics, and pharmacogenomics. It argues that integrating multi-omics with computational and machine-learning methods may improve patient stratification and therapy selection, but clinical translation still requires validation, standardization, and large trials.
Key findings
- Across omics layers, many candidate signatures are reported: a six-metastasis-related gene set; 50 DEGs from 375 TCGA GC samples with 10 linked to outcome and macrophage infiltration; 39 prognostic gene signatures with COL1A1, COL1A2, and EGFR each identified three times; an 11-DMS methylation signature; an eight-MDEG signature; 110 differentially expressed miRNAs with a three-miRNA prognostic signature; 18 immune-related lncRNAs; 429 differentially expressed proteins; 24 survival-associated metabolites with 8 independent prognostic metabolites; and a 28-metabolite model with AUROC 0.832 and concordance index 0.83, in which 11 metabolites significantly discriminated prognosis.
- Pharmacogenomic and therapeutic prediction studies identified a three-gene platinum-response model (ND6, BRMS1, SRXN1) from 23 survival-related genes; in silico TCGA analysis predicted up to 15% of GC samples would benefit from currently approved targeted therapy versus 50% from FDA-approved alternative targeted therapies; proteomic subtypes from 206 pretreatment tumor samples were linked to XELOX, DOS, and anti-HER2 therapy; and four serum metabolites distinguished chemo-sensitive from chemo-resistant tumors with 82.5% sensitivity and specificity.
- Multi-omics integration remains challenging: TCGA and ACRG molecular classifications exist but clinical use is limited by intricacy, and no alternative marker set has yet outperformed them; a deep-learning autoencoder using RNA-seq, miRNA-seq, and DNA methylation identified two prognostic subgroups and outperformed PCA and similarity network fusion. Three bioinformatics-based GC clinical trials are ongoing (NCT06035250, NCT05319392, NCT05985577) and one is completed (NCT05620537).
- Microbiome analysis of 128 samples detected 5,450 phylotypes belonging to 19 phyla and 296 genera; enrichment of *Fusobacterium nucleatum* and *Prevotella* I in cancerous tissues was associated with worse survival.
Methods
- Non-systematic review based on electronic searches of PubMed and Google Scholar using keywords including “gastric cancer”, “bioinformatics analysis”, “multi-omics”, “artificial intelligence”, “machine learning”, “prognosis”, “prediction”, and “biomarker”.
- Included review articles and guidelines from 2018 to 2023 on bioinformatic approaches to GC genetic, epigenetic, transcriptomic, proteomic, and metabolic processes; only full English articles published within the last ten years were considered. Exclusions were duplicate articles, studies lacking diagnostic outcomes, case reports, correspondence, letters, and non-human research.
- No primary data collection, systematic quality appraisal, or meta-analysis was performed; the paper summarizes cited studies and tabulated biomarker examples.
Limitations
- The paper states that this is a non-systematic review and lists obstacles to clinical implementation: need for large phenotypically characterized datasets, high accuracy and reproducibility, difficulty obtaining suitable tissue samples, strict sample preparation requirements, high costs, incompatible data across databases, need to normalize patient characteristics such as age, race, and stage, and validation through comprehensive cohort studies and large-scale clinical trials; data standardization and benchmarking of integration methods are also needed.
- Evident from the text and tables: many cited biomarker studies rely on public databases and/or small cohorts (e.g., n=18, 31, 37, 48, 65 in some tables), with limited external validation, and no systematic quality appraisal or quantitative synthesis is reported.
- Evident: as a narrative review, it does not provide new experimental validation and cannot establish the clinical utility of the listed candidate markers.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
81 Valid · 4 Not valid · 12 Not checked · 12 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“Ten of the fifty genes (RXRG, AGT, BCHE, UBE2QL1, PLCXD3, ADCYAP1R1, NRCAM, MAMDC2, CDH19, and GAMT) were linked with the outcome and macrophage infiltration in GC.”
§ Bioinformatics Analysis and Validation of Potential Markers Associated with Prediction and Prognosis of Gastric Cancer > 2. Genomics-Based Validation of Predictive and Prognostic Markers of GC
What the sources say
- Supportedcites [14] Gao W. Yang M. Identification by Bioinformatics Analysis of Potential Key Genes Related to the Progression and Prognosis of Gastric Cancer Front. Oncol. 2022 12 881015 10.3389/fonc.2022.881015 35600357 PMC9114743 source
The Results (Survival Analysis) identify these exact ten genes among fifty as having prognostic significance in gastric cancer. The Results (Relationship Between Gene Expression and Immune Cell Infiltration) report that the ten genes’ expression was most closely related to macrophages, with correlations of varying strength. (LLM, conf=0.91)
plainstates an associationn = 375- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Based on 375 TCGA GC samples, 50 DEGs between GC and paired normal tissues were identified [14].”
§ Bioinformatics Analysis and Validation of Potential Markers Associated with Prediction and Prognosis of Gastric Cancer > 2. Genomics-Based Validation of Predictive and Prognostic Markers of GC
What the sources say
- Partly supportedcites [14] Gao W. Yang M. Identification by Bioinformatics Analysis of Potential Key Genes Related to the Progression and Prognosis of Gastric Cancer Front. Oncol. 2022 12 881015 10.3389/fonc.2022.881015 35600357 PMC9114743 sourceExperimental — accuracy not yet measured
The Data Collection section reports 375 TCGA primary cancers and 32 non-tumor tissues, and the Results report a comparison between gastric cancer and normal tissues. But Screening of Differentially Expressed Genes reports 3,213 differential genes; Intersecting Genes identifies 50 genes at the intersection with a trend-analysis module. The copy does not describe the normal tissues as paired with the cancers. No page numbers are available in our copy. (LLM, conf=0.90)
plainstates an associationn = 375- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Interestingly, metabolic patterns changed before- and after surgical procedures in GC.”
§ Bioinformatics Analysis and Validation of Potential Markers Associated with Prediction and Prognosis of Gastric Cancer > 6. Metabolomics-Based Validation of Predictive and Prognostic Markers of GC
What the sources say
- Supportedcites [63] Song G. Wang L. Tang J. Li H. Pang S. Li Y. Liu L. Hu J. Circulating metabolites as potential biomarkers for the early detection and prognosis surveillance of gastrointestinal cancers Metabolomics 2023 19 36 10.1007/s11306-023-02002-0 37014438 PMC10073066 source
The Results section, “Metabolic differences before and after surgery,” explicitly states that metabolic patterns differed before and after surgery, particularly in gastric cancer (GC) subjects. It reports a comparison of plasma metabolomics from the same subjects at both time points. (LLM, conf=0.95)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Besides, highly expressed extracellular matrix proteins (THSD4, SRPX2, TGFBI, THBS1, and LAMB2) can serve as indicators to predict drug resistance.”
§ Bioinformatics Analysis and Validation of Potential Markers Associated with Prediction and Prognosis of Gastric Cancer > 7. Pharmacogenomics-Based Validation of Predictive Markers of GC
What the sources say
- Supportedcites [72] Li Y. Xu C. Wang B. Xu F. Ma F. Qu Y. Jiang D. Li K. Feng J. Tian S. Proteomic characterization of gastric cancer response to chemotherapy and targeted therapy reveals new therapeutic strategies Nat. Commun. 2022 13 5723 10.1038/s41467-022-33282-0 36175412 PMC9522856 source
The Results section, “Proteomic subtyping of the GC cohort and their association with a therapeutic response” (page not provided), names all five proteins and reports higher expression in a chemotherapy non-sensitive group. It concludes that these extracellular matrix proteins are associated with drug resistance and could indicate chemotherapy response. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“A major GC target identified in this analysis was the high frequency of PIK3CA mutation variants.”
§ Bioinformatics Analysis and Validation of Potential Markers Associated with Prediction and Prognosis of Gastric Cancer > 7. Pharmacogenomics-Based Validation of Predictive Markers of GC
What the sources say
- Supportedcites [70] Hescheler D.A. Plum P.S. Zander T. Quaas A. Korenkov M. Gassa A. Michel M. Bruns C.J. Alakus H. Identification of targeted therapy options for gastric adenocarcinoma by comprehensive analysis of genomic data Gastric Cancer 2020 23 627 638 10.1007/s10120-020-01045-9 32107691 PMC7305081 source
The Discussion describes a major gastric-cancer target identified by the analysis as the high incidence of PIK3CA mutation variants. The Results section on mutation variants identifies the relevant mutation hotspots. The citing sentence is a close paraphrase. (LLM, conf=0.95)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
48 more claims · 41 with their cited sources checked
Create a free account to see all 109 claims and to verify the 2 references still open.
- It may state two separate claims as one. 25
- Probably not a substantial claim. 38
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Bioinformatics Analysis and Validation of Potential Markers Associated with Prediction and Prognosis of Gastric Cancer > 2. Genomics-Based Validation of Predictive and Prognostic Markers of GC
“Among the six common hub genes, TRYOBP and C1QB were negatively associated with the overall survival (OS) of the GC patients.”
§ Bioinformatics Analysis and Validation of Potential Markers Associated with Prediction and Prognosis of Gastric Cancer > References
“Identification of TYROBP and C1QB as Two Novel Key Genes With Prognostic Value in Gastric Cancer by Network Analysis”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Bioinformatics Analysis and Validation of Potential Markers Associated with Prediction and Prognosis of Gastric Cancer > 6. Metabolomics-Based Validation of Predictive and Prognostic Markers of GC
“Seventeen differential metabolites (sulfite, TG (54:2), TG (53:4), G3P, α-aminobutyric acid, α-CEHC, dodecanol, glutamyl alanine, 3-methyl alanine, 3-hydroxysteroid, CL (63:4), PE-NMe (40:5), retinol, MG (21:0/0:0/0:0), tetradecanoic acid, tridecanoic acid, octacosanoic acid and myristate glycine)”
§ Bioinformatics Analysis and Validation of Potential Markers Associated with Prediction and Prognosis of Gastric Cancer > 6. Metabolomics-Based Validation of Predictive and Prognostic Markers of GC
“sulfite, TG (54:2), TG (53:4), G3P, α-aminobutyric acid, α-CEHC, dodecanol, glutamyl alanine, 3-methyl alanine, 3-hydroxysteroid, CL (63:4), PE-NMe (40:5), retinol, MG (21:0/0:0/0:0), tetradecanoic acid, tridecanoic acid, octacosanoic acid and myristate glycine”
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109 · cited 1×
“Gastric cancer (GC) is a common cancer type, with more than one million new cases each year [1].”
BackgroundWGCNA: an R package for weighted correlation network analysis
Langfelder, P., & Horvath, S. (2008) · BMC Bioinformatics · doi:10.1186/1471-2105-9-559 · Cited by 27,252
RNA-Seq: a revolutionary tool for transcriptomics
Wang, Z., Gerstein, M., & Snyder, M. (2009) · Nature Reviews Genetics · doi:10.1038/nrg2484 · Cited by 13,174 · cited 1×
“Transcriptomes denote all RNA molecules created in a cell from the genome under certain pathological situations [29,30].”
BackgroundSTRING v10: protein–protein interaction networks, integrated over the tree of life
Szklarczyk, D., Franceschini, A., Wyder, S., Forslund, K., Heller, D., Huerta-Cepas, J., Simonovic, M., Roth, A., Santos, A., Tsafou, K. P., et al. (2015) · Nucleic Acids Research · doi:10.1093/nar/gku1003 · Cited by 10,436 · cited 1×
“…interaction (PPI) networks and weighted gene co-expression network analysis (WGCNA) based on the RNA sequencing and microarray data have been revealed to establish potent organized biological strategies for mining the functional gene modules and detecting novel prognostic biomarkers [11,12].”
MethodBang, Y.-J., Van Cutsem, E., Feyereislova, A., Chung, H. C., Shen, L., Sawaki, A., Lordick, F., Ohtsu, A., Omuro, Y., Satoh, T., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61121-x · Cited by 7,302 · cited 1×
“Despite these advances in knowledge only one oncogenic driver-based therapy (Her2-directed treatment with trastuzumab) has shown acceptable survival benefit [5].”
BackgroundComprehensive molecular characterization of gastric adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13480 · Cited by 6,498 · cited 1×
“The fusion of this evidence has prompted TCGA and the Asian Cancer Research Group (ACRG) to propose several molecular classifications [77,78].”
BackgroundNomograms in oncology: more than meets the eye
Balachandran, V. P., Gonen, M., Smith, J. J., & DeMatteo, R. P. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71116-7 · Cited by 3,292 · cited 1×
“The nomogram has been broadly utilized as a predictive method in oncology for a decade [23].”
MethodMolecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes
Cristescu, R., Lee, J., Nebozhyn, M., Kim, K.-M., Ting, J. C., Wong, S. S., Liu, J., Yue, Y. G., Wang, J., Yu, K., et al. (2015) · Nature Medicine · doi:10.1038/nm.3850 · Cited by 2,223 · cited 1×
“The fusion of this evidence has prompted TCGA and the Asian Cancer Research Group (ACRG) to propose several molecular classifications [77,78].”
BackgroundSimilarity network fusion for aggregating data types on a genomic scale
Wang, B., Mezlini, A. M., Demir, F., Fiume, M., Tu, Z., Brudno, M., Haibe-Kains, B., & Goldenberg, A. (2014) · Nature Methods · doi:10.1038/nmeth.2810 · Cited by 2,036 · cited 1×
“…[97], iClusterPlus [98], Patient-specific data fusion (PSDF) [99]), network and pathway integration (e.g., Similarity network fusion (SNF) [100], PaintOmics [101], MultiGSEA [102], multi-omics gene-set analysis (MOGSA) [103], Cytoscape [104]), fusion-based integration (e.g., Protein…”
BackgroundThe NIH Roadmap Epigenomics Mapping Consortium
Bernstein, B. E., Stamatoyannopoulos, J. A., Costello, J. F., Ren, B., Milosavljevic, A., Meissner, A., Kellis, M., Marra, M. A., Beaudet, A. L., Ecker, J. R., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt1010-1045 · Cited by 1,892 · cited 1×
“Similar to genomics, an increasing number of evidence suggests that epigenetic modifications, including DNA methylation of CpG islands, post-translational modifications of histones, and nucleosome positioning, are also comprised in the GC initiation, progression, and chemo-resistance [21].”
Background
Cited by
Applications and challenges of biomarker-based predictive models in proactive health management
Zhao, Q., Zhang, C., Zhang, W., Zhang, S., Liu, Q., & Guo, Y. (2025) · Frontiers in Public Health · doi:10.3389/fpubh.2025.1633487 · Cited by 81
Beyond Biomarkers: Machine Learning-Driven Multiomics for Personalized Medicine in Gastric Cancer
Ma, D., Fan, C., Sano, T., Kawabata, K., Nishikubo, H., Imanishi, D., Sakuma, T., Maruo, K., Yamamoto, Y., Matsuoka, T., et al. (2025) · Journal of Personalized Medicine · doi:10.3390/jpm15050166 · Cited by 34
Self-citationMeng, X., Lang, Y., Li, X., Li, Y., Bu, Z., Wu, Y., & Zhang, S. (2025) · Pharmacological Research - Modern Chinese Medicine · doi:10.1016/j.prmcm.2025.100639 · Cited by 12
Applications and advances of multi-omics technologies in gastrointestinal tumors
Liu, Y., Gao, F., Cheng, Y., Qi, L., & Yu, H. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1630788 · Cited by 21
Jin, Q., Chang, Z., Chen, K., Jiang, N., Chen, G., & Lu, Y. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1690200 · Cited by 9
Revolutionizing infectious disease surveillance: Multi-omics technologies and AI-driven integration
Aswini, R., Saranya, B., Gayathri, K., & Elumalai, K. (2025) · Decoding Infection and Transmission · doi:10.1016/j.dcit.2025.100061 · Cited by 21
Li, M.-P., Long, S.-P., Liu, W., Long, K., & Gao, X.-H. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1419040 · Cited by 7
Kim, N., Na, S., Pyo, J., Jang, J. S., Lee, S., & Kim, K. W. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25179341 · Cited by 6
“This approach offers a cost-effective and scalable method to screen large datasets, predict drug targets, and explore indications for personalized medicine [61].”
MethodExploring the Spectrum of Long Non-Coding RNA CARMN in Physiological and Pathological Contexts
Li, H., Sun, C., Luo, B., Zhan, C., Li, W., Deng, L., Kang, K., & Gou, D. (2024) · Biomolecules · doi:10.3390/biom14080954 · Cited by 8
“Gastric cancer (GC), a prevalent malignancy, has a poor five-year survival rate under 30% for advanced stages [41].”
Background(2025) · doi:10.1080/08923973.2025.2470344 · Cited by 5
“Despite significant advancements in early detection and treatment, the prognosis for gastric cancer remains poor, particularly in advanced stages of the disease [2].”
Solomon, D. D., Ko, C., Chen, H., Kumar, S., Wulandari, F. S., Xuan, D. T. M., Lin, H., Lin, H.-R., Lee, Y., Hsu, W.-H., et al. (2025) · Briefings in Bioinformatics · doi:10.1093/bib/bbaf583 · Cited by 15
“Using several different hyper-parameter options for both binary and multiclass classif ication for ML and DL approaches, the study provides a deeper understanding of biomarker significance and predictive capabilities of each combination [26–28].”
Yan, Y., Li, Y.-B., Liang, H., Chen, D., Li, B., & Murshed, A. (2025) · Current Pharmaceutical Biotechnology · doi:10.2174/0113892010332329241119104430 · Cited by 7
Fan, X., Shi, J., Shang, Y., & Xu, H. (2026) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2026.1795133 · Cited by 8
“Multiomics liquid biopsy overcomes the “dimensional deficiency” of single-omics approaches by leveraging diverse integration strategies and bioinformatics (Matsuoka and Yashiro, 2024), as well as artificial intelligence (AI) technologies (He et al., 2023).”
Bioinformatics and experimental validation identify biomarkers for diagnosing Alzheimer’s disease
Liu, H., Li, C., Zhai, C., Li, M., & Ma, L. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1566929 · Cited by 4
“Through bioinformatics, this study identifies biomarkers with high specificity, offering valuable insights for the specific diagnosis of AD, as well as for clinical trials, cellular studies, and animal models (Matsuoka and Yashiro, 2024).”
Lu, Y., Huang, Y., Mao, C., Shan, P., Wu, C., Zhu, J., Lin, Y., Li, Z., & Lu, M. (2025) · Biomaterials Research · doi:10.34133/bmr.0209 · Cited by 4
“Despite these therapies extending overall survival to some extent, the 5-year survival rate for advanced GC patients remains below 30% [ 4 ].”
Multidisciplinary analysis of the prognosis and biological function of NUBPL in gastric cancer
Liu, L., Zhang, F., Yu, J., Dong, P., Deng, J., Liu, W., Cao, X., Huang, J., Lin, X., & Xue, X. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1603898 · Cited by 3
Xiong, Z., Shu, K., & Jiang, Y. (2025) · Biomedicines · doi:10.3390/biomedicines13040840 · Cited by 3
“Bioinformatic analysis has become an important method in the field of data integration [17].”
Luo, Q., Yang, S., & Xu, Q. (2025) · Digestive Diseases and Sciences · doi:10.1007/s10620-025-09402-3 · Cited by 3
Screening, Analysis, and Validation of Endoplasmic Reticulum Stress-Related DEGs in Epilepsy
(2025) · doi:10.1007/s10571-025-01567-9 · Cited by 3
“In recent years, bioinformatics has become an invaluable tool for identifying disease-related biomarkers and therapeutic targets (Matsuoka & Yashiro 2024).”
Qiu, W., Zhang, K., Hu, W., & Liu, D. (2025) · OncoTargets and Therapy · doi:10.2147/ott.s528050 · Cited by 3
“Referencing the research paradigm of Tasuku Matsuoka et al, 92 the eight genes risk score model we developed can be technically transformed into a clinically applicable testing kit, providing patients with personalized prognosis assessments.”
Hakami, M. A. (2025) · Schizophrenia Research · doi:10.1016/j.schres.2025.05.026 · Cited by 6
Li, Z., Luo, P., Zhou, Z., Cao, J., & Zhang, W. (2025) · Stem Cell Research & Therapy · doi:10.1186/s13287-025-04768-7 · Cited by 2
“As advancements in bioinformatics continue, we can anticipate significant breakthroughs in the fight against gastric cancer [16].”
Value of Bioinformatics Models for Predicting Translational Control of Angiogenesis
Shaposhnikov, M., Thakar, J., & Berk, B. C. (2025) · Circulation Research · doi:10.1161/circresaha.125.325438 · Cited by 4
“25 26–28 In addition, predictive models improve the reproducibility and robustness of scientific findings.”
Emerging Omic-derived biomarkers for early diagnosis of non-small cell lung Cancer
Wei, X., Xu, M., Wang, Y.-C., Huang, H., Chen, Q., Chen, B., Bao, X.-H., & Li, J. (2025) · Clinica Chimica Acta · doi:10.1016/j.cca.2025.120617 · Cited by 3
Effects of SB939 are mediated by STAT3 to inhibit breast cancer cell metastasis‑related genes
Qin, C., Zhang, S., Huo, X.-O., Song, R., & Ling, J. (2025) · Oncology Letters · doi:10.3892/ol.2025.14982 · Cited by 2
“Bioinformatics analysis can be used to screen vital disease‑associated proteins and provide direction for clinical research (38).”
Bao, X., Zeng, Z., Tang, W., Li, D., Fan, X., Chen, K., Wang, Y., Ai, W., Yang, Q., Liu, S., et al. (2025) · Cancer Medicine · doi:10.1002/cam4.70759 · Cited by 3
Unveiling gastric precancerous stages: metabolomic insights for early detection and intervention
Zhang, X., Lin, Z., Xu, B., Ma, C.-Y., Jiang, B., Geng, Y., Sheng, Y., Dai, Y., Xue, Y., & Ren, Y. (2025) · BMC Gastroenterology · doi:10.1186/s12876-025-03898-9 · Cited by 5
“The metabolites discovered using this approach have shown broad research prospects and clinical applications in disease etiology, early diagnosis, and prognosis [30, 31].”
Liu, X., Alimujiang, A., Wei, W., Xu, D., Wufuer, T., Abuduwayiti, J., Huo, S., & Li, Z. (2025) · Journal of Chromatography B · doi:10.1016/j.jchromb.2025.124538 · Cited by 2
In silico pan-cancer analysis of VRAC subunits and their prognostic roles in human cancers
Paolì, A., Sadeghi, S., Battistello, G., Carpanese, V., & Checchetto, V. (2025) · Scientific Reports · doi:10.1038/s41598-025-97078-0 · Cited by 3
Clinical advances and challenges of anti-angiogenic targeted therapy in gastric cancer
Wu, Z., Ni, J., & Xu, Q. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1654300 · Cited by 6
“By integrating multidimensional data from genomics, transcriptomics, proteomics, metabolomics, and other relevant fi elds, researchers have obtained a more comprehensive understanding of the molecular typing and precise treatment of GC (149 – 152).”
Computational identification and validation of non-coding rna biomarkers in gastrointestinal cancer
Al-Assi, G., Abdulsahib, W. K., Mustafa, W. W., Jyothi, S. R., Nayak, P. P., Janney, J. B., Singh, G., Sinha, A., & Sultanov, R. (2025) · Functional & Integrative Genomics · doi:10.1007/s10142-025-01747-2 · Cited by 3
“To maximize the benefits of multi-omics datasets in clinical translation, it is crucial to create and manage omics data accurately, as well as select the appropriate data merging methods for computer analysis that accompany it (Matsuoka and Yashiro 2024; Chen et al. 2022a).”
Chen, H., Zhao, S., Pen, P., Shan, Y., Gong, Y., Zhang, H., Li, Y., Lu, H., Bai, M., & Duan, Y.-Q. (2025) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2025.120503 · Cited by 4
Yi, Z., Zhang, Q., Tao, T., Liu, X., Li, H., Li, X., & Zhang, Z. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1586790 · Cited by 1
The predictive value of MISP for the postoperative outcomes of gastric cancer
Xiao, J. I. N., Xin, L., Hao, W. A. N. G., Yunpeng, L. I. N., & Zhou, Y. (2025) · Biomedical Research · doi:10.2220/biomedres.46.93 · Cited by 1
Identification and verification of the key genes involved in gallbladder cancer
Tang, J., Zhou, H., Lu, M., Cao, D., Zhang, Y., & Zhou, S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1643366 · Cited by 1
Maharani, D., Widyardhita, M. H., Widayanti, W. R., Yoga, I. M. B. K., Irmasari, I., Fatimah, N., Ujiantari, N. S. O., Putri, D. D. P., & Hermawan, A. (2026) · Cytotechnology · doi:10.1007/s10616-026-00917-9 · Cited by 1
DNMT1 blocks SOX21-repressed CKS2 transcription to promote gastric cancer progression
Wei, J., Xue, S., Du, X., Dai, Y., Ji, Y., & He, G. (2025) · BMC Cancer · doi:10.1186/s12885-025-14577-z · Cited by 1
Artificial Intelligence and Bioinformatics in the Malignant Progression of Gastric Cancer
Matsuoka, T., & Yashiro, M. (2025) · Applied Sciences · doi:10.3390/app152011092 · Cited by 2
Self-citationSYK identified by bioinformatics analysis promotes the proliferation of multiple myeloma
Deng, J., Li, P., Li, S., Liang, F., Hong, M., Zhang, T., Tan, Y., Ren, F., Zhang, Y., Xu, Z., et al. (2025) · Expert Review of Hematology · doi:10.1080/17474086.2025.2505724
“The integration of bioinformatics approaches with multi-omics platforms has emerged as a transformative strategy for identifying prognostic signatures and therapeutic targets in oncology [23].”
Li, L., Cai, W., Han, H., Chen, S., Long, B., Zhang, G., Jiang, X., Zhou, H., Qin, L., Yu, Z., et al. (2026) · Cancer Management and Research · doi:10.2147/cmar.s559532
“Current approaches to predict treatment response, including repeated histopathological evaluations, 7–9 advanced molecular profiling, 10 specialized imaging techniques, 11,12 and gene expression profiling 13 are often costly, invasive, technically complex, and not universally accessible.”
Zhao, Y., Linghu, T., Wang, Q., Gao, X., Qin, X., & Tian, J. (2026) · Analytical Chemistry · doi:10.1021/acs.analchem.6c00087
Wang, T., Tan, J., Bi, Z., Ma, L., Wang, S., Zhang, F., & Fang, Z. (2025) · Current Medicinal Chemistry · doi:10.2174/0109298673422926251009064453
(2026) · doi:10.1038/s41388-026-03914-6
“In the training cohort, gastric tissue specimens were collected from 234 patients with con fi rmed GC (T0 – T4) and 96 healthy individuals with normal gastric mucosa as controls.”
Endocrine disruption in metabolic disorders: Biomarkers and therapeutic targets
Ikram, H. M., Rehman, K., Akash, M. S. H., & Ameer, F. (2025) · Advances in clinical chemistry · doi:10.1016/bs.acc.2025.10.012
Xue, S., Dong, X., Wei, J., et al. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1763139
Tu, H.-S., Chen, M.-L., Hong, J., Li, S., & He, L. (2026) · World Journal of Gastroenterology · doi:10.3748/wjg.118672
Li, L., Cai, W., Han, H., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-7001726/v1
Zhao, J., Agu, D., Li, X., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-7523494/v1
Lipoprotein metabolism and its impact on life expectancy
Skrzycki, M., & Graboń, W. (2025) · Experimental Gerontology · doi:10.1016/j.exger.2025.112952
Bo, S., Jiang, T., You, Y., Tian, S., Bai, B., Cheng, Y., Gao, Y., & Wang, Y. (2026) · Cancer Genetics · doi:10.1016/j.cancergen.2026.01.004
Li, M.-F., Song-nan, D., Bao, P.-T., & Li, Y.-G. (2026) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.118614
Zhao, J., Agu, D., Li, X., et al. (2025) · Discover Oncology · doi:10.1007/s12672-025-04208-1
“The amalgamation of bioinformatics analysis and machine learning techniques is a more effective strategy for biomarker discovery, promising to openning new avenues for diagnosis, prognosis, and treatment of gastric cancer [12].”
MASE-GC: a multi-omics autoencoder and stacking ensemble framework for gastric cancer classification
Liu, D., Che, Z., Xu, G., & Huang, Y. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1704237 · Cited by 2
Introduction to Precision Medicine and Personalized Treatment in Acute Care and Emergency Surgery
Lakshmanan, V., Bhattacharya, P., & Mukherjee, R. (2026) · Hot topics in acute care surgery and trauma · doi:10.1007/978-3-032-09357-8_3
Wang, P., Liu, T. C., Xiong, X., Ding, X., Xie, C., & Zhang, J. (2026) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.70990
“Over the past few years, bioinformatic analysis has become a useful approach for integrating data from diverse databases for predicting effective therapeutic targets and for identifying relevant biomarkers for diagnosis and prognosis in cancers [17–19].”
Huang, C., Wu, H., Zhang, S., Feng, W., Liu, Z., Hua, C., Chen, D., Han, G., Gao, Y., 张恒辉, et al. (2026) · Phytomedicine · doi:10.1016/j.phymed.2026.158846
Cai, Y., Feng, X., Xiao, M., Li, Q., Tao, X., & Li, P. (2025) · Genes · doi:10.3390/genes16111294
“Integrated analysis of GEO datasets enables the systematic identification of core genes with diagnostic or prognostic value [11].”
Cheng, J., Cai, R., Lu, W., Zhang, Z., Liang, H., Chen, H., Zheng, H., Fang, J., Liu, Y., Li, R., et al. (2025) · Genes & Genomics · doi:10.1007/s13258-025-01704-0
“…are now capable of rapidly assessing the expression of thousands of genes across a spectrum of diseases (Mo et al. 2022; Yao et al. 2021 ; Matsuoka and Yashiro 2024 ) This capability enables a deeper compre - hension of disease pathogenesis at the genetic level, shed - ding light on the…”
Research progress in the application of metal nanoparticles in the early diagnosis of gastric cancer
Wang, S., Li, J., Zhang, Z., Bian, Y., Xi, X., He, R., Shao, Y., & Ma, C. (2026) · Nanotechnology Reviews · doi:10.1515/ntrev-2025-0351
“Biomarker detection plays a crucial role in the early screening, accurate diagnosis, and prognostic evaluation of GC, representing a shift from traditional pathological assessment to molecular-level diagnosis [94].”
Tao, S., & Yang, H. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1785100
Shi, C., Wang, Q., Zhang, X., Wang, W., Wei, Z., Wei, Z., & Liu, Y. (2025) · BMC Gastroenterology · doi:10.1186/s12876-025-04253-8
“Advances in genomic technologies have catalyzed the application of bioinformatics in gene expression profiling, enabling researchers to uncover therapeutic targets and biomarkers across various diseases [15].”
Glycogen metabolic dysfunction in T2DM with MASLD: linking α-hydroxybutyrate to GYS2 downregulation
Zhang, Z., Chen, N., Yuan, X., Li, J., & Zhou, W. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1860017
“Advances in bioinformatics now enable novel approaches to addressing these complex scientific challenges, empowering deeper exploration of pathophysiological mechanisms in T2DM with MASLD (16, 17).”
Hou, X., Zhang, Z., Cao, M., Du, Y., & Wang, X. (2025) · Discover Oncology · doi:10.1007/s12672-025-04298-x · Cited by 1
“To advance this field, integrated multi-omics analyses combined with bioinformatics and techniques such as Seahorse metabolic analysis will be crucial for systematically delineating energy metabolism dysregulation in gastric cancer [49].”
Qiu, R., Li, Z., Chen, J., He, S., Huang, M.-Y., Su, L., Wei, W., & Wu, J. (2025) · Microchemical Journal · doi:10.1016/j.microc.2025.116504
Li, X., Piao, Z. H., Lei, M., Xu, D., Jin, T., & Liu, L. (2026) · Discover Oncology · doi:10.1007/s12672-026-04967-5
“In the exploration of biomarkers, traditional differential expression analysis is inadequate for handling the explosion of multidimensional sequencing data [28, 29].”
In Silico Analysis of Squamous Cell Carcinoma
Jovičić, S. M. (2025) · Advances in experimental medicine and biology · doi:10.1007/978-3-032-03176-1_19
Bai, L., & Liu, B. (2026) · Biomarkers · doi:10.1080/1354750x.2026.2674791
Metadata
- Authors
- Matsuoka, T., & Yashiro, M.
- Affiliations
- Osaka Metropolitan University (JP)
- Corresponding author
- Yashiro, Masakazu
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2024-05-28
- Volume
- 25
- Issue
- 11
- Pages
- 5880
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC11172243
- OpenAlex
- W4399084028
- Cited by
- 83
- References
- 119
- Citations by year
- 2026: 29 · 2025: 51 · 2024: 3
- FWCI
- 6.11
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- KAKENHI (Grant-in-Aid for Scientific Research) (21H03008)
- Topics
- Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bioinformatics and Genomic Networks
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gene expression and cancer classification
- Keywords
- gastric cancer, prognostic factors, predictive biomarkers, multi-omics integration, epigenomics, transcriptomics, proteomics, metabolomics, genomics, biomarker discovery, therapeutic efficacy prediction, targeted therapy
- MeSH terms
- Humans, Prognosis, Stomach Neoplasms, Biomarkers, Tumor, Computational Biology, Genomics, Proteomics, Metabolomics, Epigenomics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.